Source: Annual Congress 2005 - Biological and molecular features in lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
M. Meral, I. Pirim, M. Akgun, H. Kaynar, L. Saglam, M. Gorguner, U. Yildirim (Erzurum, Turkey). Frequency of class I and II HLA alleles in patients with lung cancer according to responses of chemotherapy. Eur Respir J 2005; 26: Suppl. 49, 2162

Member's Comments

No comment yet.

Related content which might interest you: Influence of HLA class II  DRB1*/DQB1* alleles in phenotypes of Indian patients of sarcoidois. Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 HLA class II alleles and haplotypes are associated to the presence autoantibodies and mortality in Hypersensitivity Pneumonitis patients. Source: International Congress 2018 – Genetics in chronic pulmonary diseases Year: 2018 HLA-class I and II genotyping in sarcoidosis patients Source: Eur Respir J 2006; 28: Suppl. 50, 354s Year: 2006 ERCC1 and MDR1 expression and polymorphism frequency related to clinical outcome and chemotherapy response in a Brazilian sample of NSCLC patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 HLA class II alleles are associated with development of emphysema in alpha-1-antitrypsin deficiency (AATD) Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases Year: 2008 Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005 Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 A retrospective analysis of risk factors for Durvalumab related interstitial lung disease after chemoradiotherapy in Stage III NSCLC Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020 Association of XPD and CDA polymorphisms with clinical outcome in non-small cell lung cancer in a Chinese population Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Effect of cardiovascular comorbidities on the survival patients with stage I and II non-small-cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Associations between allergen-specific IgE sensitization and HLA class II alleles in the EGEA cohort Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020 Association of KIR genes and their ligands with non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Systemic therapy. non small cell lung cancer stage I and II: treatment standards and new development Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003 Stage I lung cancer patients with or without symptoms – are the patients any different? Source: Virtual Congress 2020 – Screening and early lung cancer Year: 2020 Clinical study for monochemotherapy of amrubicin, a topoisomerase II inhibitor, in patients with previously treated small cell lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 433s Year: 2007 Major histocompatibility complex class II and BTNL2 associations in sarcoidosis Source: Eur Respir J 2013; 42: 550-553 Year: 2013 Improved results after preoperative concurrent chemotherapy and high dose radiation therapy in selected cases with stage III N2 lung cancer? Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012